Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 AND SODIUM CHLORIDE 0 9 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride provides potassium ions for maintaining intracellular osmolarity, acid-base balance, and nerve impulse transmission; dextrose is a carbohydrate source for energy metabolism; sodium chloride provides sodium and chloride ions for extracellular fluid balance and osmotic pressure.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion, 1000 mL to 2000 mL per 24 hours, adjusted based on serum potassium, glucose, and sodium levels.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Potassium: not applicable (regulated by homeostasis); dextrose: <30 minutes; sodium: not applicable.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Potassium: renal (90%), fecal (10%); dextrose: metabolized to CO2 and water; sodium: renal (95%).
Category C
Category A/B
Electrolyte
Electrolyte